Toplum Kökenli Pnömoni
Özet
Toplum kökenli pnömoni (TKP), hastaneye yatışı olmayan bireylerde günlük yaşam sırasında gelişen ve özellikle ileri yaş ile ek hastalığı bulunan kişilerde ciddi mortalite riski taşıyan evrensel bir sağlık sorunudur. Bu enfeksiyonların en önemli etkenlerinden biri olan Streptococcus pneumoniae (pnömokok), dünya genelinde yılda yaklaşık iki milyon ölüme yol açmaktadır. Bakteri, nazofarenkste semptomsuz kolonize olabildiği gibi solunum epitelini istila ederek bakteremi, menenjit ve ampiyem gibi invaziv pnömokok hastalıklarına da neden olabilmektedir. TKP tanısı; ateş, öksürük ve dispne gibi klinik bulguların yanı sıra göğüs radyografisindeki infiltrasyonlar ve CURB-65 skorlaması kullanılarak konulmakta, ampirik antibiyotik tedavisi genellikle 7-10 gün sürmektedir. Koruyucu hekimlik kapsamında, yüksek risk grubundaki yetişkinler ve 65 yaş üzeri bireyler için Polisakkarit (PPA23) ve Konjuge (KPA13) olmak üzere iki tip aşı mevcuttur. Bağışıklık yanıtını optimize etmek adına risk gruplarına öncelikle KPA, ardından en erken sekiz hafta sonra PPA23 uygulanması ve aşılama takvimine hassasiyetle uyulması tavsiye edilmektedir.
Community-acquired pneumonia (CAP) is a global health problem that develops during daily life in previously healthy individuals and carries a significant risk of mortality, particularly in the elderly and those with comorbidities. Streptococcus pneumoniae (pneumococcus), one of the primary causative agents of these infections, accounts for approximately two million deaths annually worldwide. The bacterium can colonize the nasopharynx asymptomatically or invade the respiratory epithelium, leading to invasive pneumococcal diseases such as bacteremia, meningitis, and empyema. Diagnosis of CAP is established through clinical signs including fever, cough, and dyspnea, combined with pulmonary infiltrates on chest radiography and the CURB-65 scoring system, while empirical antibiotic treatment typically lasts 7-10 days. Within preventive medicine, two types of vaccines, Polysaccharide (PPSV23) and Conjugate (PCV13), are available for high-risk adults and individuals over 65 years old. To optimize the immune response, it is recommended to administer PCV first, followed by PPSV23 at least eight weeks later, and to strictly follow the vaccination schedule for risk groups.
Referanslar
Yağcı İ, Sarıkaya S. (2020). The effects of COVID-19 on Physical Medicine and Rehabilitation in Turkey in the first month of pandemic, Turk J Phys Med Rehab, 66(3):244-251
Bridy‐Pappas AE, Margolis MB, Center KJ, Isaacman DJ. (2005). Streptococcus pneumoniae: description of the pathogen, disease epidemiology, treatment, and prevention, Pharmacother J. Hum. Pharmacol. Drug Ther, 25(9): 1193–1212.
Geno KA, Gilbert GL, Song JY, et al. (2015). Pneumococcal capsules and their types: past, present, and future, Clin. Microbiol. Rev, 28(3): 871–899.
Berical AC, Harris D, Dela CS, Possick JD. (2016). Pneumococcal vaccination strategies: An update and perspective, Annals of the American Thoracic Society, 13(6): 933–944.
Huang SS. Johnsonb KM, Rayc TG. et al. (2011). Healthcare utilization and cost of pneumococcal disease in the United States, Vaccine, 29(18):3398–3412.
Halasa NB, Shankar SM, Talbot TR et al. (2007). Incidence of invasive pneumococcal disease among individuals with sickle cell disease before and after the introduction of the pneumococcal conjugate vaccine, Clin. Infect. Dis, 44(11): 1428–1433.
Kumashi P, Girgawy E, Tarrand JJ, Rolston KV, Raad II, Safdar A. (2005). Streptococcus pneumoniae bacteremia in patients with cancer: disease characteristics and outcomes in the era of escalating drug resistance (1998-2002), Medicine (Baltimore), 84(5): 303–312.
Heffernan RT, Barrett NL, Gallagher KM, et al. (2005). Declining incidence of invasive Streptococcus pneumoniae infections among persons with AIDS in an era of highly active antiretroviral therapy, 1995–2000. J Infect Dis, 191:2038–2045.
Ziad A. Memish, Malak Almasri, Abdulhafeez Turkestani, Ali M. Al-Shangiti, Saber Yezli . Etiology of severe communityacquired pneumonia during the 2013. International Journal of Infectious Diseases 2014; 25:186-190.
TÜSAD Eğitim Kitapları Serisi. Pnömoni. 2017; Ocak sayısı
Erten HÇ, Koah Hastalarında İnfluenza Ve Pnömokok Aşıları İçin Aşılama Oranlarının Tespit Edilmesi Ve Aşılamayı Etkileyen Faktörlerin Belirlenmesi, Sağlık Bilimleri Üniversitesi Süreyyapaşa Göğüs Hastalıkları Ve Göğüs Cerrahisi, Tıpta Uzamanlık Tezi, İstanbul, 2020.
Şenol, Esin, Azap A, Erbay A, Alp-Çavuş S, Karakuş R, Acar A. (2018). Erişkin Bağışıklamasının Hedefindeki Aşılardan Biri Olarak Pnömokok Aşısı: Türk Klinik Mikrobiyoloji ve İnfeksiyon Hastalıkları Derneği Erişkin Bağışıklaması Çalışma Grubu Uzlaşı Raporu, Klimik Dergisi, 31(1): 2-18.
Musher DM, Sampath R, Rodriguez-Barradas MC. (2011). The potential role for protein-conjugate pneumococcal vaccine in adults: what is the supporting evidence?, Clin. Infect. Dis, 52(5):633–40.
Grabenstein JD, Manoff SB. (2012). Pneumococcal polysaccharide 23-valent vaccine: long-term persistence of circulating antibody and immunogenicity and safety after revaccination in adults, Vaccine, 30(30): 4435–4444.
Fardows J, Siddique AB, Farhana N, Islam TB. (2015). Review Update on Pneumococcal Conjugate Vaccine: A New Hope for Reduction of Pneumococcal Disease in Bangladesh, Bangladesh Journal of Infectious Diseases, 2(1): 19-22.
Moberley S, Holden J, Tatham DP, Andrews RM. (2013). Vaccines for preventing pneumococcal infection in adults, Cochrane Database Syst Rev, 2013(1):CD000422.
Kupronis BA, Richards CL, Whitney CG. (2003). The Active Bacterial Core Surveillance Team. Invasive pneumococcal disease in older adults residing in long-term care facilities and in the community, Journal of the American Geriatrics Society, 51(11):1520–1525.
Cafiero-Fonseca ET, Stawasz A, Johnson ST, Sato R, Bloom DE. (2017). The full benefits of adult pneumococcal vaccination: A systematic review. PLoS ONE, 12(10): e0186903.
Esposito S, Bonanni P, Maggi S, Tan L, Ansaldi F, Lopalco P, et al. (2016). Recommended immunization schedules for adults: Clinical practice guidelines by the Escmid Vaccine Study Group (EVASG), European Geriatric Medicine Society (EUGMS) and the World Association for Infectious Diseases and Immunological Disorders (WAidid), Human Vaccines and Immunotherapeutics, 12(7):1777– 1194.
